Literature DB >> 17689597

Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation.

Emanuela Castigli1, Stephen A Wilson, Abdallah Elkhal, Esra Ozcan, Lilit Garibyan, Raif S Geha.   

Abstract

BACKGROUND: Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is a receptor used by B cell-activating factor of the TNF family and a proliferation-inducing ligand (APRIL) to induce isotype switching independently of CD40 and is mutated in patients with common variable immunodeficiency.
OBJECTIVE: We sought to determine whether TACI and CD40 cooperate in inducing class switch recombination and immunoglobulin production.
METHODS: Naive mouse B cells were stimulated with suboptimal concentrations of anti-CD40 plus IL-4 in the presence or absence of APRIL or anti-TACI. IgG(1) and IgE production was measured by means of ELISA. mRNA for Cgamma(1) and Cepsilon germ-line transcripts, activation-induced cytidine deaminase, and mature gamma(1) and epsilon transcripts were measured by means of RT-PCR. Plasmablasts were enumerated by using syndecan-1/CD138 staining. Interferon regulatory factor 4, B lymphocyte-induced maturation protein 1, and IL6 mRNA expression was measured by using quantitative PCR.
RESULTS: TACI ligation enhanced IgG(1) and IgE secretion by naive murine B cells stimulated by anti-CD40 plus IL-4, with little effect on B-cell proliferation or class switch recombination. In contrast, TACI ligation of anti-CD40 plus IL-4-stimulated B cells induced a significant increase in syndecans-1/CD138-positive cells. TACI ligation caused a modest but significant increase in the expression of interferon regulatory factor 4, with no detectable change in B lymphocyte-induced maturation protein 1 expression.
CONCLUSION: TACI and CD40 signaling converge to promote B-cell differentiation into plasmablasts. CLINICAL IMPLICATIONS: Our data suggest that TACI dysfunction could contribute to the impaired antibody response to T-dependent antigens in common variable immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689597      PMCID: PMC2121612          DOI: 10.1016/j.jaci.2007.06.012

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

2.  Regulation of the T-independent humoral response by TACI.

Authors:  G U von Bülow; J M van Deursen; R J Bram
Journal:  Immunity       Date:  2001-05       Impact factor: 31.745

3.  The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells.

Authors:  Cory Ahonen; Eric Manning; Loren D Erickson; Brian O'Connor; Evan F Lind; Steven S Pullen; Marilyn R Kehry; Randolph J Noelle
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

4.  The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity.

Authors:  Heather A Minges Wols; Gregory H Underhill; Geoffrey S Kansas; Pamela L Witte
Journal:  J Immunol       Date:  2002-10-15       Impact factor: 5.422

5.  B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Authors:  S Xu; K P Lam
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

6.  The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential for CD40-mediated immunoglobulin class switching.

Authors:  Haifa Jabara; Dhafer Laouini; Erdyni Tsitsikov; Emiko Mizoguchi; Atul Bhan; Emanuela Castigli; Fatma Dedeoglu; Vadim Pivniouk; Scott Brodeur; Raif Geha
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

7.  DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL.

Authors:  Mikhail B Litinskiy; Bernardetta Nardelli; David M Hilbert; Bing He; Andras Schaffer; Paolo Casali; Andrea Cerutti
Journal:  Nat Immunol       Date:  2002-08-05       Impact factor: 25.606

Review 8.  Mechanism and control of class-switch recombination.

Authors:  John P Manis; Ming Tian; Frederick W Alt
Journal:  Trends Immunol       Date:  2002-01       Impact factor: 16.687

9.  Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

Authors:  M Muramatsu; K Kinoshita; S Fagarasan; S Yamada; Y Shinkai; T Honjo
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

10.  TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation.

Authors:  X Z Xia; J Treanor; G Senaldi; S D Khare; T Boone; M Kelley; L E Theill; A Colombero; I Solovyev; F Lee; S McCabe; R Elliott; K Miner; N Hawkins; J Guo; M Stolina; G Yu; J Wang; J Delaney; S Y Meng; W J Boyle; H Hsu
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  32 in total

Review 1.  Innate signaling networks in mucosal IgA class switching.

Authors:  Alejo Chorny; Irene Puga; Andrea Cerutti
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

2.  Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients.

Authors:  Suresh Pallikkuth; Sudheesh Pilakka Kanthikeel; Sandra Y Silva; Margaret Fischl; Rajendra Pahwa; Savita Pahwa
Journal:  J Allergy Clin Immunol       Date:  2011-07-12       Impact factor: 10.793

3.  Role of B cells in common variable immune deficiency.

Authors:  Sam Ahn; Charlotte Cunningham-Rundles
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

Review 4.  The regulation of IgA class switching.

Authors:  Andrea Cerutti
Journal:  Nat Rev Immunol       Date:  2008-06       Impact factor: 53.106

5.  Protective antiviral antibody responses in a mouse model of influenza virus infection require TACI.

Authors:  Amaya I Wolf; Krystyna Mozdzanowska; William J Quinn; Michele Metzgar; Katie L Williams; Andrew J Caton; Eric Meffre; Richard J Bram; Loren D Erickson; David Allman; Michael P Cancro; Jan Erikson
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

6.  Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome.

Authors:  Javier Chinen; Monica Martinez-Gallo; Wenli Gu; Montserrat Cols; Andrea Cerutti; Lin Radigan; Li Zhang; Lorraine Potocki; Marjorie Withers; James R Lupski; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2011-04-22       Impact factor: 10.793

7.  Differential induction of plasma cells by isoforms of human TACI.

Authors:  Yolanda Garcia-Carmona; Montserrat Cols; Adrian T Ting; Lin Radigan; Frank J Yuk; Li Zhang; Andrea Cerutti; Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2015-01-28       Impact factor: 22.113

8.  Naturally occurring mutation affecting the MyD88-binding site of TNFRSF13B impairs triggering of class switch recombination.

Authors:  Maria B Almejun; Montserrat Cols; Marta Zelazko; Matias Oleastro; Andrea Cerutti; Pablo Oppezzo; Charlotte Cunningham-Rundles; Silvia Danielian
Journal:  Eur J Immunol       Date:  2013-01-18       Impact factor: 5.532

9.  The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function.

Authors:  John J Lee; Ingrid Rauter; Lilit Garibyan; Esra Ozcan; Tatyana Sannikova; Stacey R Dillon; Anthony C Cruz; Richard M Siegel; Richard Bram; Haifa Jabara; Raif S Geha
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

10.  Increased expression of TACI on NOD B cells results in germinal centre reaction anomalies, enhanced plasma cell differentiation and immunoglobulin production.

Authors:  Viqar S Banday; Radha Thyagarajan; Mia Sundström; Kristina Lejon
Journal:  Immunology       Date:  2016-08-23       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.